# Immuneering Corp: Form 10-Q for the period ended Jun 30, 2022

- Company: [Immuneering Corp](/companies/imrx.md) (CIK 1790340)
- Form: 10-Q
- Filed: 2022-08-10
- Accepted by EDGAR: Aug 10, 2022, 16:09 ET
- Period: 2022-06-30
- Accession: 0001558370-22-013063
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1790340/000155837022013063/imrx-20220630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1790340/000155837022013063/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $94.4k | us-gaap:Revenues |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $278.1k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2022-04-01 to 2022-06-30 | $47.9k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2022-01-01 to 2022-06-30 | $138.8k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2022-04-01 to 2022-06-30 | $46.5k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2022-01-01 to 2022-06-30 | $139.3k | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-04-01 to 2022-06-30 | $8.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-01-01 to 2022-06-30 | $17.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | −$11.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | −$24.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | −$11.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | −$24.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | −$0.44 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | −$0.93 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | −$0.44 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | −$0.93 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 26,386,343 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 26,372,787 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | −$21.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $280.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-06-30 | $87.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-06-30 | $129.2m | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $142.0m | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $3.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-06-30 | $8.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-06-30 | $133.6m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1790340/000155837022013063/imrx-20220630x10q.htm

Filed Aug 10, 2022.
Source: SEC EDGAR, the filing index for accession 0001558370-22-013063. Last ingested by Listed: Nov 10, 2026, 03:06 ET. No prices; not investment advice.
